SEL + FIR + CILO + Placebo to match FIR + Placebo to match CILO + Placebo to match SEL

Phase 2Completed

1 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Nonalcoholic Steatohepatitis

Conditions

Nonalcoholic Steatohepatitis

Trial Timeline

Mar 21, 2018 → Nov 19, 2019

NCT ID

NCT03449446

About SEL + FIR + CILO + Placebo to match FIR + Placebo to match CILO + Placebo to match SEL

SEL + FIR + CILO + Placebo to match FIR + Placebo to match CILO + Placebo to match SEL is a phase 2 stage product being developed by Gilead Sciences for Nonalcoholic Steatohepatitis. The current trial status is completed. This product is registered under clinical trial identifier NCT03449446. Target conditions include Nonalcoholic Steatohepatitis.

What happened to similar drugs?

0 of 6 similar drugs in Nonalcoholic Steatohepatitis were approved

Approved (0) Terminated (3) Active (3)

🔄IVA337 + PlaceboInventivaPhase 3

❌SEL + Placebo to match SEL 6 mg + Placebo to match SEL 18 mgGilead SciencesPhase 3

🔄MGL-3196 + PlaceboMadrigal PharmaceuticalsPhase 3

❌Elafibranor + PlaceboGenfitPhase 3

🔄Aramchol free acid + PlaceboGalmed PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03449446	Phase 2	Completed	Mar 21, 2018	Nov 19, 2019	Nonalcoholic Steatohepatitis

Competing Products

20 competing products in Nonalcoholic Steatohepatitis

See all competitors

Product	Company	Stage	Hype Score
VK2809 + Placebos	Viking Therapeutics	Phase 2	32
TERN-501 + TERN-101	Terns Pharmaceuticals	Phase 2	32
TERN-101	Terns Pharmaceuticals	Phase 2	32
TERN-201	Terns Pharmaceuticals	Phase 1	26
Lanifibranor	Inventiva	Phase 2	29
IVA337 + Placebo + Empagliflozin	Inventiva	Phase 2	29
IVA337 + Placebo	Inventiva	Phase 3	41
Colesevelam Hcl	Daiichi Sankyo	Phase 2	35
Tirzepatide + Placebo	Eli Lilly	Phase 2	35
AZD2693	AstraZeneca	Phase 2	35
Roflumilast + Pioglitazone + Placebo + Placebo	AstraZeneca	Phase 2	27
MK-3655 + Placebo	Merck	Phase 2	27
Efinopegdutide 20 mg/mL + Semaglutide 1.34 mg/mL	Merck	Phase 2	35
SEL + Placebo to match SEL 6 mg + Placebo to match SEL 18 mg	Gilead Sciences	Phase 3	32
Seladelpar + Placebos	Gilead Sciences	Phase 2	27
Cilofexor	Gilead Sciences	Phase 1	29
Firsocostat + Fenofibrate	Gilead Sciences	Phase 1	29
GS-9674 + Placebo to match GS-9674	Gilead Sciences	Phase 2	35
GS-9450 + GS-9450 Placebo	Gilead Sciences	Phase 2	35
Semaglutide + Firsocostat + Cilofexor	Gilead Sciences	Phase 2	35